Avalyn Pharma Prices $300M Nasdaq IPO for Respiratory Drug Reformulations
Avalyn Pharma prices $300M Nasdaq IPO focused on respiratory drug reformulations, betting on de-risked development timelines and payer leverage.
BeOne Secures Option on HH160 Trispecific Antibody in $2B Deal with Huahui
BeOne secures option on HH160 trispecific antibody targeting PD-1, CTLA-4, and VEGF-A in $2B deal with Huahui Health.
AbbVie Partners with Plexium on RAS Degrader Program for $1.45B
AbbVie's $1.45B partnership with Plexium aims to develop RAS degraders using molecular glue chemistry to target hard-to-drug cancer mutations.
Chiesi Acquires KalVista for $1.9B to Add Ekterly to HAE Portfolio
Chiesi acquires KalVista for $1.9B to add Ekterly, an oral on-demand treatment for hereditary angioedema, to its rare disease...
Teva Acquires Emalex for $700M Tourette’s Drug Ecopipam
Teva acquires ecopipam, a Tourette's drug targeting D1 dopamine receptors, for $700M upfront plus $200M in contingent milestones.
Agios Delivers Q1 2026 Financial Results & Business Update
Agios reported a sharp step-up in Q1 2026 performance on the back of its U.S. launch of Aqvesme (mitapivat)...
Roche to Showcase Ophthalmology Portfolio Data at ARVO 2026
Roche will unveil more than 45 ophthalmology abstracts at ARVO 2026, headlined by real-world data showing that Vabysmo improves...
Mesoblast Reports Strong Ryoncil Revenue, Improved Cash Spend
Mesoblast reported a pivotal quarter: commercial sales of Ryoncil approached $100 million in the first year since launch, quarterly...
Organogenesis Completes Rolling BLA Submission for Renu®
Organogenesis has completed a rolling Biologics License Application to the FDA for ReNu, a cryopreserved amniotic suspension allograft intended...
Zealand & Roche Advance Petrelintide to Phase 3 Trials
Zealand Pharma and Roche will advance petrelintide, a once-weekly amylin analog for chronic weight management, into Phase 3 trials...